IMTX Stock Overview
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Immatics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.34 |
| 52 Week High | US$13.60 |
| 52 Week Low | US$5.75 |
| Beta | 0.56 |
| 1 Month Change | -11.65% |
| 3 Month Change | -20.11% |
| 1 Year Change | -10.42% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.13% |
Recent News & Updates
Recent updates
Immatics launches $110M stock offering
Oct 10Cancer immunotherapy biotech Immatics up 18% on 4x normal volume
Jul 19Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation
Jan 29
Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher
Dec 16Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results
Apr 01What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?
Jan 18Immatics reports Q3 results
Dec 02Immatics (IMTX) Investor Presentation - Slideshow
Nov 13Shareholder Returns
| IMTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.3% | -0.8% | 1.7% |
| 1Y | -10.4% | 4.4% | -9.6% |
Return vs Industry: IMTX underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: IMTX matched the US Market which returned -9.6% over the past year.
Price Volatility
| IMTX volatility | |
|---|---|
| IMTX Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IMTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: IMTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 382 | Harpreet Singh | https://www.immatics.com |
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell.
Immatics N.V. Fundamentals Summary
| IMTX fundamental statistics | |
|---|---|
| Market Cap | US$635.73m |
| Earnings (TTM) | US$36.66m |
| Revenue (TTM) | US$162.92m |
17.3x
P/E Ratio3.9x
P/S RatioIs IMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMTX income statement (TTM) | |
|---|---|
| Revenue | €150.91m |
| Cost of Revenue | €101.89m |
| Gross Profit | €49.02m |
| Other Expenses | €15.06m |
| Earnings | €33.96m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 32.48% |
| Net Profit Margin | 22.50% |
| Debt/Equity Ratio | 0% |
How did IMTX perform over the long term?
See historical performance and comparison